Brief: Cns Pharmaceuticals Says Enrollment Of 229 Of Expected 243 Patients In Ongoing Study Evaluating Berubicin For Treatment Of Recurrent GBM

CNS Pharmaceuticals

11/10/2023 13:53

Oct 11 (Reuters) - CNS Pharmaceuticals Inc  CNSP.O :
    * CNS PHARMACEUTICALS INC - ENROLLMENT OF 229 OF EXPECTED
243
PATIENTS IN ONGOING STUDY EVALUATING BERUBICIN FOR TREATMENT OF
RECURRENT GBM
    * CNS PHARMACEUTICALS INC - ON TRACK TO ACHIEVE COMPLETE
ENROLLMENT OF STUDY BEFORE YEAR END
    * CNS PHARMACEUTICALS INC - ALSO EXPECT TO REPORT RESULTS
FROM THE
INTERIM ANALYSIS LATER THIS QUARTER

Source text for Eikon:  ID: 
Further company coverage:  CNSP.O 

 ((Reuters.Briefs@thomsonreuters.com))